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Abstract: Anaplasmosis is a tick-born and potential zoonotic disease caused by Anaplasma (A.)
phagocytophilum, A. ovis, A. platys and A. capra. Anaplasma marginale affecting bovines and camels
causing significant economic losses. Camels as an integral part of the socio-economic lifestyle of
nomads in semi-arid to arid ecosystems are prone to suffer from subclinical Anaplasma infections. This
study aimed to determine the performance and adaptation of commercial competitive Anaplasma ELISA
(cELISA) as a tool for screening the seroprevalence of anaplasmosis whitin the camel populations in
Egypt. This study was based on the serological investigation of 437 camel sera collected between 2015
and 2016 during a Q fever prevalence study in Egypt using commercially available cELISA for the
detection of antibodies specific for Anaplasma in bovine serum. The receiver operating characteristic
(ROC) curve, an analysis method for optimizing cutoff values in cELISAs, was used to estimate
the sensitivity and specificity using 76 true as serological positive (n = 7) and negative (n = 60)
for Anaplasma antibodies. ROC curve analysis was done for 7 true positive and 60 true negative
bovine samples and 7 true positive and 29 true negative camel samples serum. Real time PCR
and/or conventional PCR was applied to confirm Anaplasma spp. specific-DNA in camel serum
as an indication of a true positive and true negative for ROC analysis. Chi square analysis was
performed to estimate the association between risk factors and anaplasmosis in camels. The cutoff
value was determined as 0.42 (p value ≤ 0.001). Data simulation with randomly generated values
revealed a cutoff value of 0.417 (p ≤ 0.001) with resulting 58.1% Se and 97.8% Sp. Seven true positive
and 29 true negative camel serum samples was confirmed by PCR. Using the estimated cut off, the
seroprevalence in the Nile Valley and Delta and the Eastern Desert domain was 47.4% and 46.4%,
respectively. The potential risk factors as domains and origin of animals were less significantly
associated with the prevalence of anaplasmosis (domains: χ(2) = 41.8, p value ≤ 0.001 and origin:
χ(2) = 42.56, p value ≤ 0.001). Raising awareness especially for veterinarians and animal owners will
significantly contribute to the best understanding of anaplasmosis in camels in Egypt. Alternative
(in silico) validation techniques and preliminary prevalence studies are mandatory towards the control
of neglected anaplasmosis in the camel population.
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1. Introduction
Camels are utilized for milk, meat, wool and hide production as well as for transport since 4000
BC [1]. Most camel populations are kept in India and at the Horn of Africa [1]. In Egypt, the camel
population has steadily increased between 2002 and 2015 [2].
Anaplasma and Ehrlichia are obligate intracellular alphaproteobacteria and belonging to order
Rickettsiales, family Anaplasmataceae that are transmitted to vertebrate hosts by ticks of the family
Ixodidae and cause symptoms similar to febrile diseases in humans and domestic animals like the
camel [3,4]. Anaplasmosis often occurs in animals of tropical and subtropical regions but also in North
America, Europe and the Mediterranean region [3,5]. Anaplasmosis can be transmitted mechanically
by ticks, tabanid vectors, iatrogenically and transplacentally [5]. Anaplasmosis usually manifests as a
subclinical infection or as co-infection in camels [6]. El-Naga and Barghash, 2016 reported clinical cases
with fever, enlarged lymph nodes, anemia and jaundice in camels [7]. Other studies and deposited
sequences (NCBI) indicated the presence of Anaplasma camelii, A. marginale, A. centrale, A. ovis and
A. platy DNA in camels [8].
Routine diagnosis of anaplasmosis in camels is based on clinical signs and microscopic examination
of blood samples. Proper selection of currently available diagnostic assays to obtain the maximal
confirmation potential was dependent upon recording the detailed clinical history that identifies the
time interval from the onset of symptoms appearance to the investigation of the clinical specimens [9].
Although the indirect fluorescent antibody technique (IFAT) is one of the most commonly used
tests, ELISA has more advantages over it, since results can be obtained directly through a microplate
reader, which make it possible to evaluate a larger number of serum samples and avoiding problems
with doubtful interpretations [10].
Real-time PCR assay is considered as a rapid, sensitive and accurate diagnostic adjunct when
compared with direct blood smear analysis for the identification of anaplasmosis. Serologic detection
correlates poorly with PCR or blood smear analysis and more accurately reflects the collective exposure
history occurring from late in the acute infection period into convalescence [9].
Statistical approaches can significantly help amending the performance of analytical tests. Receiver
operating characteristic (ROC) curve analysis [11] and a World Organisation for Animal Health (OIE)
recommended tool [12] were commonly used to optimize the cutoff values in ELISAs to find the best
correlation for sensitivity (Se) and specificity (Sp) [13–16]. Some other methods to estimate the cutoff
values are (1) mean value plus three standard deviations of negative controls [17]; (2) Cuto f f = Xneg








These methods are based on values obtained with negative sera. Frey et al. (1998) relied on the upper
tail of the t-distribution of negative samples [20].
Anaplasmosis has been reported in some parts of Egypt in cattle, buffaloes, camels and humans.
Nevertheless, there is a lack of regular monitoring and countermeasure programs in the field. Anaplasma
marginale is most often reported and confirmed in cattle, camels and arthropods from various host
animal species. Anaplasmosis in camels was reported in Matrouh, South Sinai, Assuit and Luxor
in Egypt. The diagnosis of anaplasmosis in Egypt was dependent on cELISA, IFA, microscopic
examination and PCR [7,21–29].
A comprehensive prevalence study of camel anaplasmosis in Egypt and the adaptation of the
commercial cELISA used for bovine to test camel sera are missing. Thus, this study aimed to adapt the
commercial competitive ELISA (cELISA) used in bovines for camel sera and preliminary camel sera
prevalence was analyzed.
2. Materials and Methods
2.1. Sampling and Serological Testing
Serum samples used in this study were originally collected between October 2015 and March 2016
in Egypt for a Q fever screening study in Egypt [30].
Pathogens 2020, 9, 165 3 of 11
In total, 437 camel sera were collected from 24 governorates in Egypt. There were no sample
collected from Sinai, Assuit, and Minya. Governorates were assigned into three domains: the Western
























Age    ≤4 years  32 (16.6%)  48 (27.4%)  17 (24.6%)  97 (22.2%) 
>4 years  161 (83.4%)  127 (72.6%)  52 (75.4%)  340 (77.8%) 
Origin (Egypt/other country)  193/0 (100%/0)  13/162 (7.4%, 92.6%)  0/69 (0/100%)  206/231 (47.1%/52.9%) 
Husbandry 
Stable  0  15 (8.6%)  0  15 (3.4%) 
Nomadic  193 (100%)  133 (76.0%)  69 (100%)  395 (90.4%) 
Missing  0  27 (15.4%)  0  27 (6.2%) 













Figure 1. Geographical location of randomly selected sampling sites (red dots) in Egypt using GPS
data. Delta (D), Nile Valley (N), Western Desert (WD) and Eastern Desert (ED).
Data including age (≤4 or >4 years), husbandry system (stable/stationary, pasture and nomadic)
and tick infestation were recorded in Table 1.
Table 1. Number (%) of animals sampled per domain with age group, origin of animals, husbandry












Age ≤4 years 32 (16.6%) 48 (27.4%) 17 (24.6%) 97 (22.2%)
>4 years 161 (83.4%) 127 (72.6%) 52 (75.4%) 340 (77.8%)




Stable 0 15 (8.6%) 0 15 (3.4%)
N madic 193 (100%) 133 (76.0%) 69 (100%) 395 (90.4%)
Missing 0 27 (15.4%) 0 27 (6.2%)
Tick infestation 0 13 (7.4%) 21 (10.0%) 34 (7.78%)
Sera were screened for specific antibo ies against Anaplasma spp. using a comm rcial comp titive
ELISA v2 (V terinary Medical Rese rch and Development Inc., Pullman, WA, USA) for the detection of
antibodies specific for Anaplasma in bovine serum samples according to the manufacturer’s instruction.
This assay had a sensitivity (98%) and spe ificity of 100% in bovines, which were calculated from data
generated by diagnostic laboratory field testing [31].
Additionally, 67 cattle samples, previously tested as serological positive (n = 7) and negative
(n = 60) for Anaplasma antibodies were included as positive and negative control serum. ROC was
used to evaluate the prediction of sensitivity and specificity [32].
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2.2. DNA Preparation and PCR Amplification
DNA was extracted from seropositive and seronegative serum samples using the High Pure PCR
Template Preparation Kit (Roche, Mannheim, Germany) according to the manufacturer’s instructions.
The concentration and quality analysis of DNA in each sample was measured using a Nano-drop1000®
(Thermo Fisher, Wilmington, NC, USA). DNA amplification was done using real time- and/or
conventional PCR.
The real time TaqManTM PCR was performed using the AmpliTest Anaplasma/Ehrlichia spp. Kit
(Amplicon Ltd., Wrocław, Poland) for quantitative detection of Anaplasma DNA according to the
manufacturer’s guidelines. The result of the cycle threshold (Ct) value ≤38 was considered ‘positive’
and samples had a Ct value between 38 and 40 were considered ‘suspected’.
Conventional PCR was performed as described previously [32]. The PCR reaction was done using
a Phusion Flash High-Fidelity PCR Master Mix (Thermo Fisher, Darmstadt, Germany) and primers
MSP-5 254 F: 5′-GCA TAG CCT CCG CGT CTT TC-3′ and MSP-5 779R: 5′-ACA CGA AAC TGT ACC
ACT GCC-3′ to amplify a 525 bp fragment of the major surface protein (MSP5) gene
2.3. Performed ROC Analyses
Diagnostic specificity, sensitivity and predictive values were determined by receiver operating
characteristic (ROC) analysis (MedCalc statistical software, version 9.3.0.0). Based on the optical
density (OD) values of the cELISA, positive and negative results ROC can be generated. Usually these
data are good coverage, which means that all values are within the control range.
Control interval = mean of Pos./Neg control± 3 ∗ standard deviation (1)
True pos.baseline
= [(mean o f pos.control− 2
∗standard deviation (smallest OD value), mean o f pos.control+ 2
∗standard deviation (greatest OD value)]
(2)
True neg.baseline
= [(mean o f neg.control− 2
∗standard deviation (smallest OD value), mean o f neg.control+ 2
∗standard deviation (greatest OD value)]
(3)
A true positive and negative baseline established the probabilities of positivity or negativity were
calculated to determine the upper/lower margin (limit) of the distribution of the control sera. The sera
with the closest values to this limit can be selected as the true positive and negative range, due to the
highest probability of positivity/negativity for further analyses.
ROC curve analysis was done for 7 true positive and 60 true negative bovine samples and 7 true
positive and 29 true negative camel serum using SPSS Statistics software® (Armonk, IBM Corp, USA,
version 19) to obtain Ct, Se and Sp values. These values were used to determine seroprevalence of
347 camel sera. In addition, the above formula was used for screened camel sera, baseline values
were obtained true positive and true negative data for using in simulation analysis. In the simulation
analysis of the 2300 field serum samples, random data (true negative = 2000 and true positive = 300)
were generated using the positivity and negativity area of each plate.
ROC analysis for data reconstruction was done with 10% expected error. It should be noticed
that wells with an optical density ≤0.20 were uncolored when inspected visually to assure a higher
probability of positivity. In addition, for this study true positive/true negative samples were confirmed
with real time PCR and/or conventional PCR with the exception of a true negative of bovine. These
were selected from a true negative baseline.
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2.4. Statistical Analyses
The metadata of collected serum in this study were categorized in age (≤4 and >4 years), tick
infestation and the animals husbandry system (stable/nomadic). A chi-square or Fisher’s exact test
was used to determine the association of the disease with these risk factors. Seroprevalences were
calculated as the proportion of positive results in a population.
3. Results
Seven true positive and 29 true negative camel serum samples were confirmed by real time PCR
as an indication of the true positive and true negative for ROC analysis.
The results of statistical analyses for threshold optimization of the cELISA V2 for use in cattle
(Figure 2A) and camel (Figure 2B) sera are shown in Table 2 and Figure 2. These values were 0.42
(p ≤ 0.001) in camels and 0.4022 (p ≤ 0.001) in cattle.
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A scatter plot of the mean optical density from cattle sera values vѕ. the sera of camels showed a 
correlated relationship (Figure 3). Percent differences vѕ. mean results of cattle and camel sera 
provided average discrepancy reported error estimates and true errors, which shows the true extend 
of the bias at a low optical density (Figure 3) [33,34]. This analysis proved good correlation between 
two tests in cattle and camel serum. 
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Figure 2. Display of the performance analysis of the cELISA Anaplasma kit V2 using true positive and
true negative samples. Both analys s showed 100% Se and Sp ((A) cattle and (B) ca els). A simulation
(C) was done with 2300 randomly g nerated data involved positives (300) or negatives (2000). This
data contain a 10% i tention l error.
A scatter plot of the mean optical density from cattle sera values vs. the sera of camels showed
a correlated relationship (Figure 3). Percent differences vs. mean results of cattle and camel sera
provided average discrepancy reported error estimates and true errors, which shows the true extend of
the bias at a low optical density (Figure 3) [33,34]. This analysis proved good correlation between two
tests in cattle and camel serum.
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Table 2. Detailed data of receiver operating characteristic (ROC) analysis for cattle, camels and a simulation for camels.
Animal
Species
Samples Area Under the Curve
Coordinates of the Curve





Low Bound Upper Bound Positive Sensitivity Specificity
Cattle 7 60 1.000 0.000 (<001) 0.000 (<001) 1 1
≤0.18 0.857 0 (100%)
≤0.40 * 1 * 0 (100%) *
≤0.61 1 0.017 (98.3%)
Camels 7 29 1.000 0.000 (<001) 0.000 (<001) 1 1
≤0.33 0.857 0 (100%)
≤0.42 * 1 * 0 (100% ) *
≤0.51 1 0.034 (96.6%)
Simulation
for camels
470 1830 0.779 0.015 0.000 (<001) 0.750 0.807
≤0.42 0.581 0.021 (97.7%)
≤0.42 * 0.581 * 0.022 (97.8%) *
≤0.42 0.581 0.022 (97.8%)
* Cut off values, Se and Sp. The simulation data were randomly generated after the true positive/true negative baseline for each plate was predicted based on the formula in the Materials
and Methods.
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Figure 3. A scatter plot of values of the cELISA Anaplasma kit V2 in camel vs. cattle sera that shows
good correlation between two tests. This good agreement favors the use in camels. The percent
difference between the analysis of cattle and camel sera is showed the true extent of the bias of optical
density (OD). This means that in this case the number of infected animals may be a little bit less/greater
than in reality.
Data simulation with randomly generated values revealed a cutoff value of 0.417 (p ≤ 0.001) with
resulting 58.1% Se and 97.8% Sp.
The overall seroprevalence of anaplasmosis in camels (34.1%) was detected after optimization
of the cELISA cutoff (Ct = 0.42). Nile Valley and Delta and Eastern Desert domains showed 47.4%
and 46.4% seroprevalences, respectively. Of the camels 95.7% that were kept nomadic showed
33.7% seroprevalence.
There was no significant associated between anaplasmosis and age, the husbandry system and
tick infestation (Table 3). The overall rate of camels infested with ticks was 10.7%. Camels younger
than 4 years were highly infected than older (41.2% vs. 32.1%). Domain and origin of animals were
found to be less significant associated risk factors for camel anaplasmosis (Table 3).
Table 3. Associated risk factors for anaplasmosis in camels in Egypt.
Risk Factors
cELISA
Chi-Quadrat-Pearson Phi and Cramer








Desert 34 22.8 17.6 X(2) = 41.8
(p value ≤ 0.001)
0.309
(p value ≤ 0.001)Nile Valley
and Delta 83 55.7 47.4
Eastern Desert 32 21.5 46.4
Total 149 100 34.1
Origin (Egypt/other country) 39/110 26.2/72.5 18.9/48.6 X(2) = 42.568(p value ≤ 0.001)
0.312
(p value ≤ 0.001)
Age group ≤4 years 40 22.2 41.2 X(1) = 2.899
(p value = 0.093)
0.080
(p value = 0.093)
>4 years 109 77.8 32.1
Husbandry
Stable 6 4.3 0.4 X(1) = 0.258
(p value = 0.61)
0.025
(p value = 0.611)Nomadic 133 95.7 33.7
missing 10 6.7 10/27 = 37
Tick
infestation 16 10.7 47.1
X(2) = 3.819
(p value = 0.148)
0.0930
(p value = 0.148)
The majority of seropositivity 77.4% (n = 31) was determined in Aswan governorate from Nile
Valley and Delta followed by 46.4% (n = 69) in red sea from Eastern Desert (Table 4).
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Table 4. Seroprevalence of anaplasmosis in camels in different governorates using cELISA.
Domain Governorate No. of Tested Camels Seroprevalence n (%)
Western Desert Area
Matrouh 91 12 (13.2%)
New valley 102 22 (21.6%)
Eastern Desert Area Red Sea 69 32 (46.4%)
Nile valley and Delta
Area
Alexandria 8 1 (12.5%)
Aswan 31 24 (77.4%)
Beheira 8 2 (2.5.0%)
Beni-Suef 10 5 (50.0%)
Cairo 8 3 (37.5%)
Dakahlia 8 3 (37.5%)
Damietta 8 3 (37.5%)
Fayoum 8 3 (37.5%)
Gharbia 6 2 (33.3%)
Giza 7 3 (42.9%)
Ismailia 7 2 (28.6%)
Kafr el-Sheikh 5 3 (60.0%)
Luxor 9 6 (66.7%)
Menofia 7 5 (71.4%)
Port Said 8 3 (37.5%)
Qena 11 4 (36.4%)
Qualyubia 1 1 (100%)
Sharkia 7 3 (42.9%)
Sohag 10 5 (50.0%)
Suez 8 2 (25.0%)
Total 437 149 (34.7%)
4. Discussion
Anaplasmosis is known in Egypt since 1966 in bovines and the presence of various species of
Anaplasma were confirmed by the use of PCR in Egypt [7].
The descriptive and analytic epidemiological methods to describe the dynamics, prevalence and
risk factors of infected populations through an improved process for data collection and plan for novel
interventions helps to improve the understanding of the disease and its control [35,36].
The commercial Anaplasma cELISA V2 kit from Pullman, USA, has been previously validated for
use in the diagnosis of A. ovis in sheep with 100% specificity (95% CI: 96.7–100%) and 100% sensitivity
(95% CI: 95.7–100%) [15] and with 96.5% sensitivity and 98.1% specificity [16].
No commercial serological test available for the detection of anti-Anaplasma antibodies in camel
serum. Thus, there was a clear need for first steps to adopt a bovine test kit for use in camels. This
study was aimed to validate the commercially available cELISA for screening the anaplasmosis in
camel serum. Subsequently this optimization test was used to estimate a preliminary prevalence of
anaplasmosis in the Egyptian camel population.
Due to a lack of a sufficient pool of true negative and true positive sera, an in silico simulation for
2300 randomly generated data with 10% error has been done and resulted in 97.8% Sp. and 58.1% Se.
The calculated lower sensitivity of the test in this study may have resulted from the included error for
estimating the true positive and true negative range. In some test plates, few camel sera had a higher
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optical density than the optical density of the negative controls. This fact shifted the results of true
positive/true negative to a higher error and to a reduced the test sensitivity. Other reasons may be
caused by a different affinity of species-specific antibodies [33] of camels vs. those of bovines as well as
the IgG deficiency of camels [37,38], which may explain the fluctuations of the area under the curve
and the different Se values as shown in Figure 3C. Truly negative and positive controls will need and
have a positive effect on future validations. In this study, 7 true positive and 29 true negative camel
serum samples were confirmed by real time PCR as an indication of a true positive and true negative
for ROC analysis.
Hence, ROC analysis as a traditionally risk prediction model has shown that this cELISA can be
used to detect anti-Anaplasma antibodies in camel sera and to estimate the preliminary prevalence of
anaplasmosis in camels. At present, it might already be used in early warning systems and to monitor
changes in the activity of the disease. Considering the increasing importance of camels in the future it
therefore makes sense to further validate the WMRD Anaplasma cELISA kit for use in camels. It has
to be stressed that there does not exist other studies to compare these in silico findings. Simulation
would have been more effective and realistic if data from other studies were available. Chi square
analyses revealed that the domain and origin of animals are the only significant risk factor (domains:
χ(2) = 41.8, p value ≤ 0.001 and origin: χ(2) = 42.56, p value ≤ 0.001). These may be due to the lack of
a proper distribution of health policies in most of the areas and the origin of animals as a source of
disease transmission through the importation.
In this study, bovine serum and bovine controls serum provided with this commercial cELISAv2
kit confirms that cELISA can be used with confidence to determine %I and to confirm the presence or
absence of anti-Anaplasma antibody in camel serum. The results of this study proved that cELISAv2
kit was validated for the detection of anti-Anaplasma antibody in camels. The cELISA used in this
study appeared to meet the criteria for use in diagnosing anaplasmosis and screening in camels for the
presence of the Anaplasma-specific antibody.
Alternative (in silico) validation techniques and preliminary prevalence studies are the first steps
towards control of neglected anaplasmosis in the generally untended but increasingly important farm
animal camel.
It can be assumed that raising of society awareness especially in veterinarians and animal owners
will significantly contributed to our understanding of anaplasmosis in Egypt.
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